Ab­b­Vie op­tions in­te­grin-based com­pounds from Mor­phic, paving way for po­ten­tial fi­bro­sis treat­ments

Al­most two years af­ter first ink­ing a deal with Ab­b­Vie worth $100 mil­lion up­front, Mor­phic Ther­a­peu­tic re­ceived an­oth­er bit of good news from the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.